Bibliography
- DINARELLO CA: Biological basis for interleukin-1 in disease. Blood (1996) 87(6):2095–2147.
- DINARELLO CA: IL-18: A T1-inducing, proinflammatory cytokine and new member of the IL-1 family. j Allergy CM]. Immurrol (1999) 103:11–24.
- ENK AH, KATZ SI: Early molecular events in the induction phase of contact sensitivity. Proc. Natl. Acad. Li. USA (1992) 89:1398–1402.
- NAIK SM, CANNON G, BURBACH GJ et al.: Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. j Invest. Dermatol (1999) 113:766–772.
- KUIDA K, LIPPKE JA, KU G et al: Altered cytokine export and apoptosis in mice deficient in interleukin-1I3 converting enzyme. Science (1995) 267: 2000-2003.
- LIP, ALLEN H, BANERJEE S et al: Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell (1995) 80:401–411.
- ANTONOPOULOS C, CUMBERBATCH M, DEARMAN RJ et al: Functional caspase-1 is required for Langerhans cell migration and optimal contact sensitization in mice. j Immurrol (2001) 166:3672–3677.
- KU G, FAUST T, LAUFFER LL et al.: Interleukin-113 converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytolone (1996) 8:377–386.
- KU G, FORD E RAYBUCK SA etal.: Selective interleukin-1I3 converting enzyme (ICE/Caspase-1) inhibition with pralnacasan (HMR 3480NX-740) reduces inflammation and joint destruction in murine type II collagen-induced arthritis (CIA). Am. Coll. Rheumatol (Abstracts) (Submitted, 2001).
- MULLICAN M, HARBESON S, LAUFFER DJ et al: Structure-based design of an orally available, selective interleukin-113 converting enzyme (caspase-1) inhibitor, pralnacasan, that inhibits inflammation and joint destruction in murine collagen-induced arthritis. (Submitted, 2001).
- LOHER F, BAUER C, SCHMALL K, etal.: The ICE inhibitor, pralnacasan, reduces DSS-induce murine colitis and Thl-cell activation. VIth International Symposium on Inflammatory Bowel Diseases Abstracts (Istanbul, Sept, 2001).
- KU G, QADRI A, RANDLE JCR: Interleukin-113 converting enzyme (caspase-1) inhibition with VX-765 reduces inflammation and cytokine levels in murine oxazolone-induced dermatitis. j Invest. Dermatol (July 2001) (Society for Investigative Dermatology Abstracts, Washington, May 2001).